XML 22 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenue:      
Total revenue $ 235,309 $ 176,319 $ 256,577
Operating costs and expenses:      
Cost of goods sold $ 12,871 $ 8,869 $ 1,147
Cost, Product and Service [Extensible List] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member]
Research and development $ 387,043 $ 252,924 $ 209,265
Selling, general and administrative 123,925 106,406 135,479
Total operating costs and expenses 523,839 368,199 345,891
Loss from operations (288,530) (191,880) (89,314)
Interest and other, net      
Interest expense (1,075) (2,402) (2,876)
Interest income and other income (expenses), net (1,078) 5,553 15,548
Total interest and other, net (2,153) 3,151 12,672
Loss before income taxes (290,683) (188,729) (76,642)
Provision for income taxes 347 360 328
Investment income (loss) in unconsolidated variable interest entity 1,007 (202) 0
Net loss $ (290,023) $ (189,291) $ (76,970)
Net loss per share - basic and diluted $ (3.14) $ (2.11) $ (0.89)
Weighted average number of common shares used to calculate net loss per share - basic and diluted 92,349 89,854 86,633
License Revenue [Member]      
Revenue:      
Total revenue $ 116,434 $ 14,323 $ 177,086
Development and Other Revenue [Member]      
Revenue:      
Total revenue 70,275 80,592 114,115
Product Revenue, Net [Member]      
Revenue:      
Total revenue 47,638 72,498 1,700
Drug Product Revenue [Member]      
Revenue:      
Total revenue $ 962 $ 8,906 $ (36,324)